FDA Accepts Supplemental Application for Argatroban by Fresenius Kabi
The FDA has accepted a supplemental application for Argatroban submitted by Fresenius Kabi.
Therapeutic Area
Therapeutic area intelligence for Anticoagulant with 22 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.